Fisetin belongs to a group of natural flavonols with a variety of biological activities, including anti-inflammatory, antioxidant, anti-tumor, anti-aging and neuroprotective effects.

METHODS: Human pancreatic cancer cells PANC-1 were treated with Fisetin (25-400 µM) for 24-48 h. Cell viability was measured by CCK-8 assay.
RESULTS: Low concentrations of Fisetin (25-50 µM) did not significantly inhibit the viability of PANC-1 cells, and high concentrations inhibited it. [1]
METHODS: HeLa cells were treated with Fisetin (20-50 µM) for 24-48 h. Cell cycle was detected by Flow cytometry.
RESULTS: Cells treated with 20/30/50 µM Fisetin resulted in a high accumulation of G2/M phase cells. The proportion of G2/M-arrested cells increased from 10.1% to 16.2%, 18.9% and 25.1%, respectively, at 24 h, whereas the proportion of G2/M-blocked cells increased to 30.9%, 36.2% and 56.2%, respectively, at 48 h. Meanwhile, at 48 h, 50 µM of Fisetin put a large proportion of cells in Go/G1 phase. [2]

METHODS: To detect anti-tumor activity in vivo, Fisetin (300 mg/kg) was administered intraperitoneally every two days for 20 days to BALB/c nude mice bearing PANC-1 xenografts.
RESULTS: Tumor size was significantly reduced in Fisetin-treated mice. proliferation-associated protein proliferating cell nuclear antigen (PCNA) was significantly reduced in the Fisetin-treated group. fisetin treatment reduced the expression of proteins associated with cell growth and proliferation, including PCNA, Ki67, and phosphorylated histone H3. [1]